
usd may pm et
summari develop small molecul therapeut treatment wide rang diseas led
cystic fibrosi anti-inflammatori condit
price-to-earnings oper ep
risk assess reflect view vertex
reliant expand cystic fibrosi cf franchis
wider patient sub-group see clear
domin leader market
jul ep estim base cfra oper earn
histor earn report compani report
cash dividend paid last year
past perform indic futur perform reli upon
analysi prepar equiti analyst
may pm stock trade
expect sale grow
approxim billion grow
sale tie
cystic fibrosi cf treatment sale
rose billion compris
revenu wherea cf sale
compris revenu
expect cf product revenu grow
year-over-year billion driven
growth sale symdeko
launch earli sale
matur product kalydeco orkambi
execut manag
month resign slightli
month later januari interim cfo
also termin find
sudden execut departur
regard capit alloc expect
focu extern innov
strategi involv activ licens
collabor like look
opportun expand cystic fibrosi
franchis set technolog tool
earli mid-stag pipelin asset
think share
fair valu see risk share
uncertainti tie execut issu henc
hold rate effort discov tripl
combin regimen treat cf could
cf popul
estim patient doubl
cf patient current estim
elig treatment
sever on-going phase trial tripl
combin regimen like file new
drug applic nda one
equival applic europ
also promis grow
exposur therapeut area includ
pain sickl cell diseas beta thalassemia
pipelin could make attract
risk opinion target price includ
failur expand cf franchis
greater-than-expect discount due payer
pushback pipelin failur poor new
target base
ep
compar rang
redistribut reproduct prohibit without written permiss copyright cfra document intend provid person invest advic take account specif invest
object financi situat particular need specif person may receiv report investor seek independ financi advic regard suitabl and/or appropri make
invest implement invest strategi discuss document understand statement regard futur prospect may realiz investor note incom
invest may fluctuat valu invest may rise fall accordingli investor may receiv back less origin invest investor seek advic concern impact
invest may person tax posit tax advisor pleas note public date document may contain specif inform longer current use make
invest decis unless otherwis indic intent updat document
corpor overview biotechnolog compani focus
develop commerci therapi treatment cystic fibrosi cf compani also
advanc research develop area includ pain sickl cell diseas beta-thalassemia
antitrypsin defici vrtx program crispr develop clinic candid
sickl cell diseas beta-thalassemia uniqu one first human trial
use power gene-edit technolog
market background cf life shorten genet diseas affect approxim peopl
north america europ australia cf caus defect miss cftr protein result
mutat cftr gene absenc work cftr protein result poor flow salt water
cell number organ includ lung result thick sticki mucu build
block passag mani organ lead varieti symptom particular mucu build
clog airway lung caus chronic lung infect progress lung damag
vrtx commerci medicin symdeko/symkevi orkambi kalydeco collect approv
treat approxim half cf patient north america europ australia believ
in-develop tripl combin regimen treatment could address cf
patient current treatabl multipl tripl combin program
phase develop expect submit least one tripl combin therapi
commerci approv
competit dynam number compani seek identifi develop drug candid
treatment cf includ public compani proqr
therapeut proteostasi therapeut well sever privat compani although
first compani success develop medicin treat underli caus cf
product collect approv treat portion patient cf futur treatment regimen
includ vrtx tripl combin regimen could deliv enhanc benefit patient
current treat vrtx medicin
impact major develop announc posit data two phase clinic trial
evalu tripl combin tezacaftor ivacaftor certain patient afflict cf
compani also launch sale symdeko
juli receiv first fda approv orkambi treat underli caus cystic
fibrosi patient older mutat approv signific mileston
enabl becom clear market leader treatment cf
subsequ obtain addit approv orkambi treat addit subset cf patient
financi trend year end decemb achiev revenu billion
year-over-year reflect compound annual growth rate compani
adjust ep prior-year gener grow level
posit free cash past three year gener maintain signific net cash posit
believ substanti financi flexibl easili fund oper
execut vice-president chief
redistribut reproduct prohibit without prior written permiss copyright cfra
base cfra proprietari quantit model
stock rank overvalu
analysi stock current worth base
cfra proprietari quantit model suggest
under-valued usd
neutral sinc april technic indic
neutral
figur base fiscal year-end price
growth rate averag
return equiti
balanc sheet data million usd
oper
long term debt capit
net incom revenu
return asset
return equiti
 global market intellig data may preliminari restat result discontinu operations/speci item per share data adjust stock dividend ep dilut
redistribut reproduct prohibit without prior written permiss copyright cfra
posit outlook biotechnolog
histor defens sub-industri
expect see commerci
develop mani new innov therapi
declin preval patent
expir biotechnolog
compani trade discount
market think remedi
robust pipelin new drug brought
market fda approv novel drug increas
shatter
previou record sinc novel
approv set think mani
drug either newly-approv
late-stag clinic trial consider
commerci prospect repres major
advanc therapi diseas
sclerosi cancer
start favor
announc mega merger agreement
celgen celg bristol-my
squibb industri debt level
still low risen last four
five year suggest may
banner year biotech merger
acquisit although
sever matur biopharmaceut firm
made mark blockbust drug
look off-set lost revenu
expir patent fail ventur
exampl see
like acquir
expect interest
off-set declin hcv therapi sale
expect engag activ make
failur late-stag alzheim
low debt level attract valuat
rel industri make
think growth biotechnolog
stock limit recent high
drug price come
heighten scrutini polit
apparatu last year despit
talk lower drug price
seen particularli sever measur taken
legisl regulatori bodi
lower drug price democrat took
hous repres
novemb mid-term elect appear
motiv address drug price
still think suffici impetu
effect signific chang near
futur anoth sourc price pressur
drug manufactur pharmaci benefit
manag pbm health insur
exert influenc drug
prescript price pressur
like increas major pbm merg
major insur cvs-aet ci-esrx
biolog price competit innov
act bpcia grant
exclus period brand biolog maker
sinc brand biolog manufactur
aggress use patent law
commerci leverag delay
commerci biosimilar
maintain market domin longer
result expect biosimilar continu
advanc slowli next sever year
year-to-d april
biotechnolog index risen mere
compar rise valu
 composit index
declin
base index
five-year market price perform may
note sector sub-industri inform base
past perform indic futur perform
reli upon
yield equiti
ltd
peer group compani stock select issu base market capit
note peer select base global industri classif standard market capit peer group list includ compani similar characterist may includ compani within
industri and/or engag line busi
redistribut reproduct prohibit without prior written permiss copyright cfra
analyst research note compani news
pm et cfra maintain hold opinion share
lower target base ratio
ep reflect recent
industry-wid multipl compress adjust ep estim
ep ep vs
higher estim product revenu increas
million driven continu launch symdeko sale symdeko
symkevi increas sequenti million million
surpris quarter overal outlook
mostli unchang compani remain track submit new drug
applic nda one tripl combin medicin
market author applic europ
welcom new cfo charli wagner note clinic molecul
treatment antitrypsin defici receiv fast-track
design fda yesterday /kevin huang cfa
pharmaceut incorpor rais
target price line peer ratio base
forward ep estim anticip continu robust sale
growth obtain addit price reimburs agreement
countri cystic fibrosi cf drug also believ tripl
combin regimen treat cf could significantli expand market
opportun trial current phase success meet primari end
point think could potenti file nda tripl combin
regimen also two pend fda action date august
expand cf treatment younger patient ep vs
ahead estim rais ep estim
ep estim sale rose driven success
launch symdeko addit countri agre price
reimburs cf drug /jeffrey loo cfa
et cfra keep buy opinion share vertex
pharmaceut incorpor keep
target above-p ratio due view robust
growth prospect base ep estim ep
vs ahead view sale cystic fibrosi
cf product rose aid launch symdeko solid growth
kalydeco orkambi symdeko receiv fda approv
treat cf patient age two copi mutat
least one mutat respons tezacraftor/ivacaftor
expect symdeko receiv eu approv believ
cf patient world-wide elig product half
patient product see signific growth potenti
pend approv cf product patient age
fda action date august kalydeco patient age
august fda action date orkambi patient age
et cfra maintain hold opinion share
maintain target slightli
averag ep ep vs
higher estim maintain ep estim
initi ep revenu increas million
driven us launch symdeko sale includ million
symdeko us regard capit alloc expect
focu extern innov strategi involv activ
licens collabor like look opportun
expand cystic fibrosi franchis set technolog tool
earli mid-stag pipelin asset exampl research
develop therapi sickl cell diseas pain patient small fiber
neuropathi beta-thalessemia provid detail
departur two cfo past sever month continu view
uncertainti signific risk /kevin huang cfa
et cfra lower opinion share hold
buy maintain target price
lower opinion share hold see increas
risk near-term share price perform what-appears-to-b c-suit
issu yesterday termin interim cfo ian smith also
compani person behavior violat vertex code
conduct valu last month then-cfo thoma graney
announc immedi resign cfo view departur two cfo
within less two month red flag addit delay
announc earn call year consist
announc first week januari past four year concern
event may indic issu compani
could innocu explan impact compani valu
see increas near-term risk due uncertainti /kevin huang cfa
et cfra reiter buy opinion share vertex
pharmaceut incorpor maintain
target slightli three-year averag
ep estim ep vs
higher estim rais ep
lower ep futur increas tax rate
sale increas million launch symdeko
symdeko saw rapid uptak across elig patient
sale million cf revenu also receiv
approv kalydeco orkambi young children continu work
develop pipelin branch cf treatment
area includ pain sickl cell diseas beta thalassemia
octob crispr announc fda lift
clinic hold investig new drug applic treatment
sickl cell diseas compani plan initi phase studi
note research note reflect cfra publish opinion analysi stock time note publish note reflect view equiti analyst date time
indic note may reflect cfra current view compani
redistribut reproduct prohibit without prior written permiss copyright cfra
fiscal year analyst estim earn
usd quarter fiscal year
announc earn per share usd repres
total revenu estim fiscal year
analyst estim earn per share grow
usd
total
estimate
forecast reliabl indic futur perform
note compani earn outlook play major part invest decis global market intellig organ earn estim wall street analyst
provid consensu earn next two year well earn estim chang time note inform provid relat consensu
estim intend predict actual result taken reliabl indic futur perform
note tabl graph chart report cite refer sourc sourc global market intellig
redistribut reproduct prohibit without prior written permiss copyright cfra
sinc januari cfra equiti fund research servic
predecessor capit iq equiti research rank univers
common stock adr american depositari receipt adss american
depositari share base given equiti potenti futur perform
similarli rank asian european equiti sinc june
rank equiti accord individu forecast equiti futur total
return potenti versu expect total return relev benchmark
region index asia europ
base time horizon star design meet need
investor look put invest decis perspect data use
assist determin star rank may result analyst
model well intern proprietari model result dynam data
also known
 growth
stabil earn dividend deem key element establish
global market intellig earn dividend rank common stock
design capsul natur record singl symbol
note howev process also take consider certain
adjust modif deem desir establish rank
final score stock measur score matrix determin
analysi score larg repres sampl stock
rang score array sampl align follow
ladder rank
cfra earn per share ep estim reflect analyst project futur
ep continu oper gener exclud variou item
view special non-recur extraordinari also ep estim reflect
either forecast equiti analyst consensu averag ep estim
independ compil global market intellig data
provid cfra among item typic exclud ep estim
asset sale gain impair restructur merger-rel charg legal
insur settlement process research develop expens gain
loss extinguish debt cumul effect account
chang earn relat oper classifi
compani discontinu inclus item stock option
expens recur type charg may vari depend
factor industri practic analyst judgment extent
type data disclos compani
equiti analyst project market price given secur command
month henc base combin intrins rel privat
cfra equiti research produc distribut account research
analyt llc d/b/a cfra cfra us togeth affili
subsidiari cfra certain research produc distribut cfra
sdn bhd compani formerli known standard poor
malaysia sdn bhd cfra malaysia certain research distribut cfra uk
limit cfra uk cfra uk cfra malaysia wholly-own subsidiari
cfra us
abbrevi use equiti research report
ebit earn interest tax
redistribut reproduct prohibit without prior written permiss copyright cfra
p/nav price net asset valu ratio price-to-earnings-to-growth ratio pv present
 research develop roce return capit employ roe
return equiti
roi return invest
 return invest capit
roa return asset
wacc weight averag capit
dividend american depositori receipt adr american depositori
share adss net tax paid countri origin
reflect equiti analyst view given compani oper risk
risk firm abil continu on-going concern qualit risk
assess rel rank star univers
reflect risk factor relat compani oper oppos risk
volatil measur associ share price etf reflect
capitalization-weight basi averag qualit risk assess
assign hold fund
star rank system definit
total return expect outperform total return relev benchmark
notabl margin come month share rise price
total return expect outperform total return relev benchmark
come month share rise price absolut basi
total return expect close approxim total return relev
benchmark come month share gener rise price
absolut basi
total return expect under-perform total return relev
benchmark come month share price anticip
total return expect under-perform total return relev
benchmark notabl margin come month share fall
price absolut basi
north america relev benchmark europ
asia relev benchmark europ asia
